Hepatotoxicity induced by bodybuilding supplements

Česká verzia

Authors: Martina Jakabovičová; Zuzana Urkovičová; Tereza Hlavatá; Mária Szántová
Authors place of work: III. interná klinika LF UK a UN, Nemocnica akademika Ladislava Dérera, Bratislava
Published in the journal: Vnitř Lék 2020; 66(1): 28-33
Category:

Summary

Bodybuilding supplements are known as anabolic-androgenic steroids (AAS), as well as dietary supplements with their addition. Without medical indications, they are illegal but easily accessible and harmful, capable of causing various forms of liver damage from the transient increase in serum enzymes through acute cholestatic syndrome to the development of hepatic tumours in long-term use. The strongest hepatotoxic effects are associated with alkylated forms, although tumours have also been associated with unmodified or esterified testosterone. Since the 1980s, they have been widespread not only in top-level sport but also in the general population to improve athletic performance and body shaping. According to epidemiological studies, there has been an increase in their use in recent years. The paper provides an overview of the most common clinical forms of hepatotoxicity resulting from using AAS.

Keywords:

anabolic‑androgenic steroids – herbal and dietary supplements (HDS) – hepatocellular carcinoma – prolonged jandice – testosterone

Zdroje

1. Navarro V, Khan I, Bjornsson E. Liver Injury from Herbal and Dietary Supplements. Hepatology 2017; 65: 363–373.

2. Navarro VJ, Barnhart H, Bonkovsky H et al. Liver Injury from Herbal and Dietary Supplements in the US Drug Induced Liver Injury Network. Hepatology 2014; 60: 1399–1408.

3. Kolibáš E Anabolické steroidy - psychiatrická problematika ich zneužívania. Alkohol Drog Záv (Protialkohol Obz) 2004; 4-5: 217–235.

4. Rahnema CD, Crosnoe LE, Kimed H. Designer steroids over the counter supplements and their androgenic component: review of an increasing problem. Andrology 2015; 3: 150–155.

5. Maravelias C, Dona A, Stefanidou M et al. Adverse effects of anabolic steroids in athletes. A constant threat. Toxicol Lett 2005; 158: 167–175.

6. Barceloux DG, Palmer RB Anabolic -androgenic steroids. Dis Mon 2013; 59: 226–248.

7. Kanayama G, Hudson JI, Pope jr. HG Illicit anabolic androgenic steroid use. Horm Behav 2010; 58: 111–121.

8. Shahidi NT. A review of the chemistry, biological action, and clinical applications of anabolic -androgenic steroids. Clin Ther 2001; 23: 1355–1390.

9. Szántová M Hepatotoxicita indukovaná herbálnou medicínou a dietetickými doplnkami. Interná med 2017; 17: 473–479.

10. Caliz IM, Cortes MG, Jimenez AG. Herbal and Dietary Supplement -Induced Liver Injuries in the Spanish DILI Registry. Clinic Gastroent and Hep 2018; 16: 1495–1502.

11. Nieschlag E, Vorona E. Doping with anabolic androgenic steroids (AAS): adverse effects on nonreproductive organs and functions. Rev Endocr Metab Disord 2015; 16: 199–211.

12. Kabíček P. Zneužívaní anabolických steroidu u dospívajícich v medzinárodním kontextu. Vox pediatriae 2005; 5: 14–15.

13. Eaton DK et al. Youth risk behavior surveillance - United States, 2007. Mortality and Morbidity Weekly Report. Surveillance Summaries 2008; 57: 1–131.

14. Eisenberg ME, Wall M, Neumark -Sztainer D. Muscle -Enhancing Behaviors Among Adolescent Girls and Boys. Pediatrics 2012; 130: 1019-1036.

15. Šimurka P, Zavrel M. Anabolické steroidy a mládež. Pediatr pro Praxi 2008; 9: 294–297.

16. Snyder PJ. Androgens. In: Hardman JG, Limbird LE, Gilman AG (eds.). Goodman and Gilman’s The Pharmacological Basis of Therapeutics. New York: McGraw Hill 2001; 1635–1648.

17. Pope jr. HG, Wood RI, Rogol A et al. Adverse health consequences of performance-enhancing drugs: an endocrine society scientific statement. Endocr Rev 2014; 35: 341–375.

18. Andrade RJ, Lucena MI, Fernandez MC et al. Drug -induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over 10-years period. Gastroenterology 2005; 129: 512–521.

19. Szántová M, Sedlačko J, Jakabovičová M. Lieková a herbálna hepatotoxicita: Prehľad klinických klasifikácií. Vnitr lek 2018; 64: 384–393.

20. Robles DM, Gonzalez JA, Medina CI. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Aliment Pharmacol Ther 2015; 41: 116–125.

21. Modlinski R, Fields KB. The effect of anabolic steroids on the gastrointestinal system, kidneys, and adrenal glands. Curr Sports Med Rep 2006; 5: 104–109.